Researchers at UAB have recently completed 2 studies investigating the safety and effectiveness of a new treatment schedule for prostate cancer using hypofractionated radiotherapy, which involves higher doses of radiotherapy per day over a shorter overall treatment time. These studies revealed that over 97% of patients with prostate cancer treated since 2005 remain cancer-free, and fewer than 1 in 10 patients experienced significant gastrointestinal side effects, such as nausea, vomiting, diarrhea, 3 months following the completion of treatment. We anticipate that these results will be confirmed by ongoing national clinical trials.

 

The success of hypofractionated treatment is based on advances in technologies such as CT-based image-guidance (IGRT) and Intensity-Modulated Radiotherapy (IMRT). IMRT techniques enable the physician to design and shape the radiation beams such that higher doses of radiation can be delivered directly to the tumor tissue, while minimizing radiation to the surrounding normal organs, such as the bladder and rectum. Also, IGRT allows for real-time positioning of the prostate at the time of treatment to ensure accurate delivery of the radiation doses, because there is day-to-day movement of the prostate and other organs. Putting these technologies together means that fewer treatment sessions are necessary to achieve the same anti-tumor effects, while simultaneously minimizing side-effects. The most common of these regimens are performed utilizing the linear accelerator located at the Kirklin Clinic at Acton Road Comprehensive Cancer Center.

In addition to these studies, investigators at UAB will soon be enrolling a trial to investigate treating prostate cancer using Stereotactic Body Radiation Therapy (SBRT), a highly focused, high dose form of radiation that is delivered in only 5 sessions using even higher doses per session. Our commitment to research allows us to ensure you receive the most up-to-date information to help you make informed decisions regarding the treatment of your prostate cancer.

Drs. Bredel and Willey Receive SPORE Grant for Research

 

Drs. Markus Bredel and Christopher Willey each received grants from the UAB Brain Tumor Spore Program to support their research in glioblastoma treatment.

BredelMarcus Bredel, M.D., Ph.D.

Research Project:"Role of NFKBIA Deletion as a Pathogenic Mechanism and Therapeutic Target in Glioblastoma"

 

 

 

 

 

IMG 0043Christopher Willey M.D., Ph.D.

Research Project: “MARCKS as a Novel Regulator of Glioblastoma Growth and Treatment Resistance"

The Division of Radiation Physics in the UAB Department of Radiation Oncology plays a vital role in achieving our established missions.  Our highly regarded staff of six Ph.D. Medical Physicists and one Masters trained Medical Physicist, provide quality-of-care support for all of our clinical services, perform research designed to enhance cancer care via the use of radiation physics, and serve the educational needs of the field through our physics teaching program.This program has a long history of innovation and in taking research into clinical practice, ranging from important work in the field of hyperthermia in the 1970’s to testing and implementation of RapidArc™ in 2008.  The department is a recognized leader in preparing medical students in the science of radiation physics, and has even had the nation’s leading board score on the physics section of the exam.  Our medical students consistently rate near the top on board scores among all radiation oncology programs.